These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32546364)
1. Laboratory monitoring of patients with hereditary tyrosinemia type I. Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364 [TBL] [Abstract][Full Text] [Related]
2. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I. la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291 [TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836 [TBL] [Abstract][Full Text] [Related]
4. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience. Yeo M; Turner C; Dalton NR; Rahman Y; Vara R Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663 [TBL] [Abstract][Full Text] [Related]
5. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day. Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874 [TBL] [Abstract][Full Text] [Related]
6. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1. Sundberg J; Wibrand F; Lund AM; Christensen M J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145 [TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures. Prieto JA; Andrade F; Lage S; Aldámiz-Echevarría L J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):671-6. PubMed ID: 21377430 [TBL] [Abstract][Full Text] [Related]
9. Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients. Davit-Spraul A; Romdhane H; Poggi-Bach J J Chromatogr Sci; 2012 May; 50(5):446-9. PubMed ID: 22511487 [TBL] [Abstract][Full Text] [Related]
10. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I. Adam BW; Lim TH; Hall EM; Hannon WH Clin Chem; 2009 Dec; 55(12):2207-13. PubMed ID: 19850631 [TBL] [Abstract][Full Text] [Related]
11. Single dose NTBC-treatment of hereditary tyrosinemia type I. Schlune A; Thimm E; Herebian D; Spiekerkoetter U J Inherit Metab Dis; 2012 Sep; 35(5):831-6. PubMed ID: 22307209 [TBL] [Abstract][Full Text] [Related]
12. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs. De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104 [TBL] [Abstract][Full Text] [Related]
13. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC). Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679 [TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648 [TBL] [Abstract][Full Text] [Related]
15. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1]. Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637 [TBL] [Abstract][Full Text] [Related]
16. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program. Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696 [TBL] [Abstract][Full Text] [Related]
17. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis. Cansever MS; Aktuğlu-Zeybek AC; Erim FB Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine. Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492 [TBL] [Abstract][Full Text] [Related]
19. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Chace DH; Lim T; Hansen CR; De Jesus VR; Hannon WH Clin Chim Acta; 2009 Sep; 407(1-2):6-9. PubMed ID: 19545553 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients. van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]